DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive: In hematologic malignancies, DPP-IV/CD26 activates and sustains the survival of acute and chronic myeloid leukemia stem cells [52,53], making this surface receptor a novel potentially targetable biomarker.